Lack of an Association between the Functional Polymorphism TREM-1 rs2234237 and the Clinical Course of Sepsis among Critically Ill Caucasian Patients-A Monocentric Prospective Genetic Association Study.
90-day mortality
TREM-1
sepsis
single nucleotide polymorphism
survival analysis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
03 Mar 2019
03 Mar 2019
Historique:
received:
01
02
2019
revised:
25
02
2019
accepted:
27
02
2019
entrez:
6
3
2019
pubmed:
6
3
2019
medline:
6
3
2019
Statut:
epublish
Résumé
Sepsis is a life-threatening condition and a significant challenge for those working in intensive care, where it remains one of the leading causes of mortality. According to the sepsis-3 definition, sepsis is characterized by dysregulation of the host response to infection. The TREM-1 gene codes for the triggering receptor expressed on myeloid cells 1, which is part of the pro-inflammatory response of the immune system. This study aimed to determine whether the functional TREM-1 rs2234237 single nucleotide polymorphism was associated with mortality in a cohort of 649 Caucasian patients with sepsis. The 90-day mortality rate was the primary outcome, and disease severity and microbiological findings were analyzed as secondary endpoints. TREM-1 rs2234237 TT homozygous patients were compared to A-allele carriers for this purpose. Kaplan⁻Meier survival analysis revealed no association between the clinically relevant TREM-1 rs2234237 single nucleotide polymorphism and the 90-day or 28-day survival rate in this group of septic patients. In addition, the performed analyses of disease severity and the microbiological findings did not show significant differences between the TREM-1 rs2234237 genotypes. The TREM-1 rs2234237 genotype was not significantly associated with sepsis mortality and sepsis disease severity. Therefore, it was not a valuable prognostic marker for the survival of septic patients in the studied cohort.
Identifiants
pubmed: 30832396
pii: jcm8030301
doi: 10.3390/jcm8030301
pmc: PMC6463065
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Volkswagen Foundation
ID : ZN3168
Références
J Immunol. 2000 May 15;164(10):4991-5
pubmed: 10799849
Nature. 2001 Apr 26;410(6832):1103-7
pubmed: 11323674
J Immunol. 2003 Apr 1;170(7):3812-8
pubmed: 12646648
J Infect Dis. 2003 Jun 15;187 Suppl 2:S397-401
pubmed: 12792857
Chest. 1992 Jun;101(6):1644-55
pubmed: 1303622
J Infect Dis. 2006 Oct 1;194(7):975-83
pubmed: 16960786
Eur J Immunol. 2007 Aug;37(8):2300-8
pubmed: 17634956
Hum Immunol. 2008 Mar;69(3):220-6
pubmed: 18396215
J Innate Immun. 2009;1(6):582-91
pubmed: 20375613
JAMA. 2010 Oct 27;304(16):1833-4
pubmed: 20978262
Cell Immunol. 2012;272(2):251-8
pubmed: 22055202
Crit Care. 2012 Jun 28;16(3):R112
pubmed: 22742734
Nat Med. 2012 Jul 06;18(7):998-9
pubmed: 22772540
Inflammation. 2012 Dec;35(6):1833-43
pubmed: 22798017
ISRN Inflamm. 2013 Feb 12;2013:431739
pubmed: 24049659
Virulence. 2014 Jan 1;5(1):45-56
pubmed: 24067565
Nat Rev Immunol. 2013 Dec;13(12):862-74
pubmed: 24232462
J Investig Med. 2014 Mar;62(3):638-43
pubmed: 24463978
Gene. 2014 Oct 15;550(1):101-9
pubmed: 25128583
PLoS One. 2015 May 28;10(5):e0127761
pubmed: 26020644
World J Emerg Med. 2015;6(2):123-30
pubmed: 26056543
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
PLoS Med. 2016 May 17;13(5):e1002022
pubmed: 27187803
Biomarkers. 2017 Feb;22(1):63-69
pubmed: 27319606
Immunol Rev. 2016 Nov;274(1):330-353
pubmed: 27782333
Sci Rep. 2017 Apr 25;7:46440
pubmed: 28440307
Sci Rep. 2017 Aug 29;7(1):9887
pubmed: 28851893
Sci Rep. 2018 Oct 11;8(1):15140
pubmed: 30310101
Cells. 2018 Dec 13;7(12):null
pubmed: 30551680
J Clin Med. 2019 Jan 10;8(1):null
pubmed: 30634576
Crit Care Med. 1985 Oct;13(10):818-29
pubmed: 3928249
Nature. 1998 Feb 12;391(6668):703-7
pubmed: 9490415
Crit Care Med. 1998 Nov;26(11):1793-800
pubmed: 9824069